Kurosu Y, Arai T, Morita K
First Department of Surgery, Nihon University School of Medicine, Tokyo, Japan.
Jpn J Surg. 1988 Mar;18(2):152-7. doi: 10.1007/BF02471424.
The effect of indomethacin, a prostaglandin synthetase inhibitor, on lymphocyte responses to phytohemagglutinin (PHA) was studied in 111 breast, stomach and colorectal cancer patients. Indomethacin exerted no mitogenic activity and the ethanol in which the indomethacin was dissolved produced no significant effect on the lymphocyte responses to PHA. Compared with the control group (13 healthy subjects and 30 patients with benign disease), indomethacin significantly enhanced the lymphocyte responses to PHA in the cancer patients. The degree of enhancement induced by indomethacin was independent of the primary site of the tumor, but was associated with tumor load. A significant inverse correlation was observed between the degree of enhancement and that of the original lymphocyte responses to PHA. Sequential determinations of the degree of enhancement in selected stomach and colorectal cancer patients revealed that it fell to a low level after curative tumor resection.
在111例乳腺癌、胃癌和结直肠癌患者中研究了前列腺素合成酶抑制剂吲哚美辛对淋巴细胞对植物血凝素（PHA）反应的影响。吲哚美辛无促有丝分裂活性，且溶解吲哚美辛的乙醇对淋巴细胞对PHA的反应无显著影响。与对照组（13名健康受试者和30名良性疾病患者）相比，吲哚美辛显著增强了癌症患者淋巴细胞对PHA的反应。吲哚美辛诱导的增强程度与肿瘤的原发部位无关，但与肿瘤负荷有关。观察到增强程度与原始淋巴细胞对PHA的反应程度之间存在显著负相关。对选定的胃癌和结直肠癌患者增强程度的连续测定显示，根治性肿瘤切除后其降至低水平。
